Massachusetts Eye and Ear Infirmary made history this week, becoming the first institution to use an FDA-approved gene therapy to treat a patient with an inherited disease.
Spark Therapeutics‘ (NSDQ:ONCE) Luxturna gene therapy, which was approved by the FDA in December, is designed to improve vision in patients with inherited retinal disease caused by a particular genetic mutation. Yesterday, Dr. Jason Comander injected the treatment into the eye of a 13-year-old boy from New Jersey.
Get the full story at our sister site, Drug Delivery Business News.
